Silexion Therapeutics Ltd.
SLXN · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $7,041 | $111,857 | $278,693 |
| - Cash | $9,243 | $3,466 | $6,152 | $1,187 |
| + Debt | $311 | $3,698 | $3,482 | $4,491 |
| Enterprise Value | – | $7,273 | $109,187 | $281,997 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$4 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$3,258 | -$2,497 | -$1,722 | -$23 |
| % Margin | – | – | – | – |
| Net Income | -$3,262 | -$2,503 | -$1,735 | -$31 |
| % Margin | – | – | – | – |
| EPS Diluted | 2.88 | 4.32 | -0.26 | -0.19 |
| % Growth | -33.3% | 1,761.5% | -36.8% | – |
| Operating Cash Flow | -$2,843 | -$2,507 | -$2,453 | -$2,926 |
| Capital Expenditures | $0 | -$1 | -$6 | $0 |
| Free Cash Flow | -$2,843 | -$2,508 | -$2,459 | -$2,926 |